Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Net Cash Flow (2018 - 2026)

10x Genomics' Net Cash Flow history spans 8 years, with the latest figure at $41.2 million for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 176.57% to $41.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $129.4 million, a 959.73% increase, with the full-year FY2025 number at $129.4 million, up 959.73% from a year prior.
  • Net Cash Flow hit $41.2 million in Q4 2025 for 10x Genomics, up from $35.0 million in the prior quarter.
  • Over the last five years, Net Cash Flow for TXG hit a ceiling of $112.4 million in Q1 2023 and a floor of -$275.9 million in Q1 2022.
  • Historically, Net Cash Flow has averaged -$10.8 million across 5 years, with a median of -$6.2 million in 2023.
  • Biggest five-year swings in Net Cash Flow: crashed 903.58% in 2022 and later soared 1051.66% in 2025.
  • Tracing TXG's Net Cash Flow over 5 years: stood at -$12.9 million in 2021, then dropped by 11.91% to -$14.4 million in 2022, then surged by 407.79% to $44.5 million in 2023, then tumbled by 221.03% to -$53.8 million in 2024, then soared by 176.57% to $41.2 million in 2025.
  • Business Quant data shows Net Cash Flow for TXG at $41.2 million in Q4 2025, $35.0 million in Q3 2025, and $20.3 million in Q2 2025.